Middle East & Africa Human Insulin Market Size, Share & COVID-19 Impact Analysis, By Type (Analog Insulin, and Traditional Insulin), By Diabetes Type (Diabetes 1, and Diabetes 2), By Distribution Channel (Hospital Pharmacy, and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Middle East & Africa holds a substantial market share in the global human insulin market. Middle East & Africa human insulin market size is projected to grow at a CAGR of 0.8% during the forecast period. The global human insulin market is projected to grow from USD 18.7 billion in 2022 to USD 21.04 billion by 2030.

The rising prevalence of type 1 diabetes in the region, growing infrastructure, and extensive presence of global insulin manufacturers have led to market growth. According to an article published by the Journal of Diabetology in December 2022, the largest company in the Middle East & Africa, Julphar, provides 0.25% of the globally registered insulin products and is among the top seven global insulin manufacturers.

Our report on the Middle East & Africa market covers the following countries/regions – GCC, South Africa, and the rest of Middle East & Africa.

LATEST TRENDS

High Human Insulin Production by Key Players in the Region to Augment Market Growth

The availability of human insulin products is limited across low-income countries in the region. Thus, several industry players and government agencies are now manufacturing new production centers across the region to improve access to diabetes treatment and quality care for patients. Moreover, the increasing availability of an extensive product portfolio owing to new production centers is set to augment Middle East & Africa human insulin market share.

• In December 2022, the Minister of Health and Population in Egypt, had announced the rollout of a new high-capacity production line for insulin by the MUP (Medical Union Pharmaceutical Company) of Egypt. The country will export insulin to African countries at a low-cost price.

DRIVING FACTORS

Rising Initiatives for Sustainable Access of Insulin in the Region to Propel Market Growth

The demand for insulin therapy is rising in the Middle East & Africa region owing to increasing awareness of diabetes care among patients. However, the costs associated with access to and therapy for diabetes treatment are high. Thus, several players are now collaborating with strategic initiatives to provide affordable human insulin to the extensive population suffering from diabetes. Such initiatives will enhance the insulin availability and sustainable access to human insulin, further boosting the market growth.

• In December 2022, Eli Lilly and Company and EVA Pharma entered a partnership for ensuring a sustainable supply of affordable, high-quality human and analogue insulin to one million people living with diabetes in low- to middle-income countries (LMICs), most in Africa.

RESTRAINING FACTORS

Request a Free sample to learn more about this report.

Lack of Adequate Infrastructure for Procurement, Insulin Supply Chain, and Insulin Distribution to Hamper Growth

The demand for the availability of human insulin among patients in middle and low-income countries is high. However, the lack of adequate infrastructure for producing human insulin across these countries and less developed healthcare facilities pose a barrier to access healthcare for patients. Also, the limited availability of insulin distribution facilities and patient awareness across the region further restrains the market growth. As per an article published by ResearchGate in 2022, the Middle East and Africa region had poor accessibility to insulin syringes, delivery systems, and glucose measurement tools in many of its low-income countries.

KEY INDUSTRY PLAYERS

The major players such as Novo Nordisk A/S, Eli Lilly and Company, and Sanofi held a prominent Middle East and Africa human insulin market share in 2022. The highest share is attributable to extensive regional product offerings and distribution networks.

Other prominent players such as Julphar and Biocon are now focusing on inorganic strategies such as the production of new R&D centers and collaborations to develop new products for diabetes care in the market. Also, rising market authorizations for existing products across Middle Eastern countries further propelled the company’s market share.

• In November 2021, BIOTON S.A. had received registration approval for its insulin products in Malta, Yemen, and Nigeria countries.

LIST OF KEY COMPANIES PROFILED:

• Novo Nordisk A/S (Denmark)


• Eli Lilly and Company (U.S.)


• Sanofi (France)


• Julphar (UAE)


• Biocon (India)


• BIOTON S.A. (Poland)


• Lupin (India)


• Exir (Iran)


• VACSERA (Egypt)


• SEDICO (Egypt)

KEY INDUSTRY DEVELOPMENTS:

• December 2022: Novo Nordisk announced the expansion of its partnership with Amalgam Rx, a U.S.-based company, for supporting the commercialization of a digital insulin initiation and titration app, dubbed Dose Check. The Dose Check digital insulin app is designed for helping people with type 2 diabetes using basal insulin.


• October 2022: Gulf Pharmaceutical Industries Company and PureHealth announced a strategic partnership to set up the first production center in the Middle East to produce Glargine (the first long-acting biological alternative to insulin) for the treatment of diabetes. The partnership enabled the UAE for obtaining an insulin substitute at more competitive prices. It also supported exports to regional and global markets with an increasing demand for insulin substitutes.


• September 2020: Eli Lilly Saudi Arabia and AJA Pharmaceutical Industries Ltd. inked an agreement for the local production of insulin within KSA and the improvement of strategic cooperation via biomedical capabilities.

REPORT COVERAGE

The market report provides a detailed market analysis. It focuses on key aspects such as the launch of new products, technological advancements, and the prevalence of diabetes. Besides this, the report offers insights into the market trends and highlights key industry developments such as mergers, partnerships, and acquisitions and the impact of COVID-19 on the market. In addition to the above mentioned factors, the report encompasses several factors that have contributed to the market's growth over recent years.

Report Scope & Segmentation